A blood gene detection method for tumors used for drug guidance

Abstract

The present invention provides a blood gene detection method for tumors for medication guidance, which belongs to the field of bioinformatics technology, and specifically includes: based on disease indicators and development data of disease indicators, determining the matching situation of the patient's disease indicators in different dimensions with preset disease stages, and determining based on the matching situation that when the matching coefficient between the patient and the preset disease stage meets the requirements, determining the position and number of gene mutation points corresponding to the target drug, and using the gene mutation data corresponding to the gene mutation points to determine the risk coefficient of drug resistance variation of the target drug, obtaining the patient's medication duration and the risk coefficient of drug resistance variation, and determining whether it is necessary to perform gene testing on the patient in combination with the patient's drug resistance risk and the matching coefficient, thereby improving the efficiency of gene testing for the patient.

Description

Technical Field

[0001] The present invention belongs to the field of bioinformatics, and in particular relates to a blood gene detection method for tumors used for drug guidance. Background Art

[0002] During the treatment of cancer, it is inevitable that a certain degree of drug resistance mutation will occur. For example, primary drug resistance (PDR) refers to the resistance to one anti-tumor drug while still being sensitive to drugs of a different type. Multidrug resistance (MDR) refers to the resistance of some cancer cells to one anti-tumor drug while also developing resistance to other drugs of a different type. It is the main reason for the failure of tumor chemotherapy.

[0003] In order to solve the problem of drug-resistant mutation detection, the invention patent application CN202310889084.8 "Detection method and application of tumor-specific mutation status" monitors tumor-specific mutations in circulating tumor DNA by superimposing cancer-specific fixed core probe groups and SNP probe groups. It can be used for recurrence risk stratification, treatment response evaluation and disease monitoring, providing important reference for clinical treatment decision-making. However, there are the following technical problems:

[0004] In the process of detecting drug-resistant mutations, due to the differences in the disease stages of different patients, if the treatment plan cannot be adjusted in a targeted manner when drug-resistant mutations occur, the impact on the patient's physical treatment progress will be different. Therefore, if the genetic testing plan cannot be determined according to the patient's disease stage, it will be impossible to improve the reliability of medication adjustments while reducing the testing cost.

[0005] In response to the above technical problems, the present invention provides a blood gene detection method for tumors for guiding medication. Summary of the invention

[0006] To achieve the purpose of the present invention, the present invention adopts the following technical solutions:

[0007] According to one aspect of the present invention, a method for blood gene detection for tumors for guiding medication is provided.

[0008] A blood gene detection method for tumors for drug guidance, specifically comprising:

[0009] S1 determines the medication matching period of the patient based on the medication data of the patient, determines the development data of different disease indicators of the patient within the medication matching period, and uses the development data to determine that the drug resistance risk of the patient is within a preset risk interval, then proceeds to the next step;

[0010] S2 determines the matching of the disease indicators of the patient in different dimensions with the preset disease stage based on the disease indicators and the development data of the disease indicators, and proceeds to the next step when the matching coefficient between the patient and the preset disease stage meets the requirements based on the matching situation;

[0011] S3 determines the location and number of gene mutation points corresponding to the target drug, and determines the risk coefficient of drug resistance change of the target drug using the gene mutation data corresponding to the gene mutation points;

[0012] S4 obtains the patient's medication duration and drug resistance change risk coefficient, and determines whether it is necessary to perform genetic testing on the patient in combination with the patient's drug resistance risk and matching coefficient.

[0013] The beneficial effects of the present invention are:

[0014] Development data is used to determine whether the patient's drug resistance risk is within the preset risk range, thereby enabling accurate assessment of the patient's drug resistance risk based on the development data of the patient's different disease indicators during the medication matching period, thereby enabling the screening of patients with a higher risk of drug resistance, and also laying the foundation for further generating differentiated genetic testing and processing strategies based on differences in patients' drug resistance risks.

[0015] Whether the patient needs to undergo genetic testing is determined based on the patient's medication duration, the risk coefficient of drug resistance change, the patient's drug resistance risk and the matching coefficient. This not only takes into account the patient's drug resistance risk and the stage of the disease, but also takes into account the differences in the patient's drug resistance testing needs caused by the patient's medication duration and the risk coefficient of drug resistance change, thereby achieving accurate determination of the patient's genetic testing strategy from multiple angles.

[0016] A further technical solution is that the medication matching period of the patient is the corresponding medication period of the patient's target drug.

[0017] A further technical solution is that the disease indicators include alpha-fetoprotein, carcinoembryonic antigen, CA125, prostate-specific antigen and PSA.

[0018] A further technical solution is that the method for determining the patient's drug resistance risk is:

[0019] Determining abnormal change indicators in the patient's disease indicators based on the development data of the disease indicators;

[0020] The drug resistance risk of the patient is determined according to the number of the abnormal change indicators.

[0021] A further technical solution is that the abnormal change index is a disease index whose change amount in the medication matching period does not meet the requirements.

[0022] A further technical solution is to determine whether it is necessary to perform genetic testing on the patient, specifically including:

[0023] Determine the risk correction coefficient of the patient based on the duration of medication for the patient, and determine the modified risk coefficient of the patient in combination with the variable risk coefficient of drug resistance of the patient;

[0024] A comprehensive risk coefficient is determined based on the patient's corrected risk coefficient, the patient's drug resistance risk, and the matching coefficient, and the comprehensive risk coefficient is used to determine whether genetic testing of the patient is required.

[0025] A further technical solution is that the comprehensive risk coefficient is determined based on the patient's modified risk coefficient, the patient's drug resistance risk, and an average value of a matching coefficient.

[0026] A further technical solution is that when the comprehensive risk coefficient is greater than a preset comprehensive coefficient threshold, it is determined that genetic testing needs to be performed on the patient.

[0027] Other features and advantages will be described in the following description. The objects and other advantages of the present invention are realized and obtained by the structures particularly pointed out in the description and drawings.

[0028] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, preferred embodiments are given below and described in detail with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] The above and other features and advantages of the present invention will become more apparent by describing in detail exemplary embodiments thereof with reference to the attached drawings.

[0030] Figure 1 It is a flow chart of a method for blood gene detection for tumors used for drug guidance;

[0031] Figure 2 is a flow chart of the method for determining a patient's risk of drug resistance;

[0032] Figure 3 is a flow chart of a method for determining a matching coefficient between a patient and a preset disease stage;

[0033] Figure 4 This is a flow chart of a method for determining a risk factor for change in drug resistance of a target drug. DETAILED DESCRIPTION

[0034] In order to enable those skilled in the art to better understand the technical solutions in this specification, the technical solutions in the embodiments of this specification will be clearly and completely described below in conjunction with the drawings in the embodiments of this specification. Obviously, the described embodiments are only part of the embodiments of this specification, not all of the embodiments. Based on the embodiments of this specification, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of this specification.

[0035] When drug-resistant mutations occur, if the treatment plan cannot be adjusted in a targeted manner, the impact on the patient's physical treatment progress will vary. Therefore, it is necessary to generate a drug resistance detection strategy based on the development of the patient's disease indicators.

[0036] The patient's drug resistance risk: The patient's drug resistance risk is determined by the number of abnormal change indicators in the patient's disease indicators. When the specific number of abnormal change indicators is 3 and the disease indicators are 10, the drug resistance risk is 0.3. When the drug resistance risk is greater than 0.5, it is determined that the patient needs to undergo genetic testing.

[0037] Matching coefficient between the patient and the preset disease stage: Determine the matching disease indicators with the preset disease stage based on the matching of disease indicators of different dimensions with the preset disease stage; determine the disease indicators whose changing amounts match the preset disease stage based on the development data of disease indicators of different dimensions, and use them as changing matching disease indicators; obtain disease indicators that are both matching disease indicators and changing matching disease indicators, and use them as screening matching disease indicators; determine the matching coefficient between the patient and the preset disease stage based on the proportion of the number of screening matching disease indicators; when the matching coefficient is greater than 0.7, it is determined that the matching coefficient between the patient and the preset disease stage meets the requirements.

[0038] Variation risk coefficient: The position of the mutation point corresponding to the target drug is taken as the matching mutation position. The number of patients with gene mutations corresponding to the matching mutation position is determined based on the gene mutation data corresponding to the matching mutation position. The position variation coefficients of different matching mutation positions are determined using the proportion of the number of patients with corresponding gene mutations. The variation risk coefficient of drug resistance of the target drug is determined based on the average value of the position variation coefficients of different matching mutation positions.

[0039] Determine whether the patient needs to undergo genetic testing: Determine the comprehensive risk coefficient based on the average of the patient's drug resistance variable risk coefficient, modified risk coefficient, and matching coefficient, and determine whether the patient needs to undergo genetic testing based on whether the comprehensive risk coefficient is above 0.3

[0040] To solve the above problems, according to one aspect of the present invention, Figure 1As shown, a method for blood gene detection for tumors for drug guidance is provided, which specifically includes:

[0041] S1 determines the medication matching period of the patient based on the medication data of the patient, determines the development data of different disease indicators of the patient within the medication matching period, and uses the development data to determine that the drug resistance risk of the patient is within a preset risk interval, then proceeds to the next step;

[0042] S2 determines the matching of the disease indicators of the patient in different dimensions with the preset disease stage based on the disease indicators and the development data of the disease indicators, and proceeds to the next step when the matching coefficient between the patient and the preset disease stage meets the requirements based on the matching situation;

[0043] S3 determines the location and number of gene mutation points corresponding to the target drug, and determines the risk coefficient of drug resistance change of the target drug using the gene mutation data corresponding to the gene mutation points;

[0044] S4 obtains the patient's medication duration and drug resistance change risk coefficient, and determines whether it is necessary to perform genetic testing on the patient in combination with the patient's drug resistance risk and matching coefficient.

[0045] Furthermore, the medication matching period of the patient is the corresponding medication period of the patient's target drug.

[0046] Specifically, the disease indicators include alpha-fetoprotein, carcinoembryonic antigen, CA125, prostate-specific antigen and PSA.

[0047] It should be noted that if Figure 2 As shown, the method for determining the patient's risk of drug resistance is:

[0048] Determining abnormal change indicators in the patient's disease indicators based on the development data of the disease indicators;

[0049] The drug resistance risk of the patient is determined according to the number of the abnormal change indicators.

[0050] It can be understood that the abnormal change index is a disease index whose change amount in the medication matching period does not meet the requirements.

[0051] It should be noted that the patient's drug resistance risk is determined according to the proportion of the number of the abnormal change indicators in the number of the disease indicators.

[0052] It should also be noted that when the patient's drug resistance risk is not within the preset risk range, when the patient's drug resistance risk is greater than the preset risk coefficient, it is determined that the patient needs to undergo genetic testing; when the patient's drug resistance risk is not greater than the preset risk coefficient, it is determined that the patient does not need to undergo genetic testing.

[0053] Optionally, the method for determining the patient's risk of drug resistance is:

[0054] Based on the development data of the disease indicator, determining the change amount of the patient's disease indicator during the medication matching period, and using the change amount to determine the change risk coefficients of different disease indicators;

[0055] The drug resistance risk of the patient is determined according to the average values ​​of the variable risk coefficients of different disease indicators.

[0056] Furthermore, the change risk coefficient is determined based on the ratio of the change amount of the disease indicator to the initial indicator data of the disease indicator.

[0057] Optionally, the method for determining the patient's risk of drug resistance is:

[0058] S11, based on the development data of the disease indicator, determining the change amount of the disease indicator of the patient in the medication matching period, and determining the basic risk coefficient of the disease indicator based on the change amount;

[0059] Optionally, the above step S11 includes steps S111-S113, which are specifically:

[0060] S111 determines the change amount of the patient's disease indicator in the medication matching period based on the development data of the disease indicator, and when there is no disease indicator whose change amount does not meet the requirement, proceeds to step S12; when there is no disease indicator whose change amount does not meet the requirement, proceeds to step S112;

[0061] S112: taking the disease indicators whose change amount does not meet the requirement as the changed disease indicators; when the number of the changed disease indicators does not meet the requirement, determining that the patient needs to be subjected to gene testing; when the number of the changed disease indicators meets the requirement, proceeding to the next step;

[0062] S113 determines the patient's basic variable risk coefficient according to the change amount of different variable disease indicators in the medication matching period. When the patient's basic variable risk coefficient does not meet the requirements, it is determined that the patient needs to undergo genetic testing. When the patient's basic variable risk coefficient meets the requirements, the basic risk coefficient of the disease indicator is determined based on the change amount, and the process goes to step S12.

[0063] S12 determines the variation of the disease indicator at different detection times in the medication matching period, and calculates the variation risk coefficient of the disease indicator based on the variation at different detection times;

[0064] Optionally, the above step S12 includes steps S121-S124, specifically:

[0065] S121 determines the variation of the disease indicator at different detection times in the medication matching period, and when the variation is used to determine the disease indicator with abnormally changed detection times, proceeds to step S122; when there is no disease indicator with abnormally changed detection times, proceeds to step S123;

[0066] S122 determines the changed disease indicators in the disease indicators according to the number of abnormal change detections. When the number of changed disease indicators does not meet the requirement, it is determined that the patient needs to be subjected to gene testing. When the number of changed disease indicators meets the requirement, the process proceeds to step S123.

[0067] S123 determines the screening risk coefficient based on the number of changed disease indicators and the number of detections of abnormal changes of different changed disease indicators. When the screening risk coefficient does not meet the requirements, it is determined that the patient needs to undergo gene testing. When the screening risk coefficient meets the requirements, the process proceeds to step S124.

[0068] S124 calculates the risk coefficient of change of the disease indicator based on the change amount at different detection times, and proceeds to step S13.

[0069] S13 determines the variable risk disease index of the patient using the variable risk coefficient and the basic risk coefficient, and determines the drug resistance risk of the patient according to the variable risk coefficients and basic risk coefficients of different variable risk disease indicators.

[0070] Optionally, the above step S13 includes steps S131-S133, specifically:

[0071] S131: when the number of disease indicators whose variable risk coefficients do not meet the requirements is greater than the preset indicator number threshold, it is determined that the patient needs to undergo gene testing; when the number of disease indicators whose variable risk coefficients do not meet the requirements is not greater than the preset indicator number threshold, the process proceeds to step S132;

[0072] S132: determining the variable risk disease index of the patient using the variable risk coefficient and the basic risk coefficient; when the number of the variable risk disease index is greater than the preset index number threshold, determining that the patient needs to undergo gene testing; when the number of the variable risk disease index is not greater than the preset index number threshold, proceeding to step S133;

[0073] S133 determines the drug resistance risk of the patient according to the variable risk coefficients of different variable risk disease indicators and the basic risk coefficients.

[0074] It should be noted that the variable risk disease index is determined based on the average value of the variable risk coefficient and the basic risk coefficient. Specifically, the disease index with an average value greater than a preset risk coefficient threshold is used as the variable risk disease index.

[0075] Specifically, Figure 3 As shown, the method for determining the matching coefficient between the patient and the preset disease stage is:

[0076] Determine the disease indicators matching the preset disease stage based on the matching conditions between the disease indicators of different dimensions and the preset disease stage;

[0077] Based on the development data of disease indicators in different dimensions, determine the disease indicator whose change amount matches the preset disease stage, and use it as the change matching disease indicator;

[0078] Disease indicators that are both matching disease indicators and changing matching disease indicators are obtained and used as screening matching disease indicators, and the matching coefficient between the patient and the preset disease stage is determined using the number of screening matching disease indicators.

[0079] Furthermore, the value range of the matching coefficient between the patient and the preset disease stage is between 0 and 1, wherein when the matching coefficient is less than a preset matching threshold, it is determined that the matching coefficient between the patient and the preset disease stage meets the requirement.

[0080] It should also be noted that the method for determining the matching coefficient between the patient and the preset disease stage is:

[0081] Determine the number of disease indicators that match the preset disease stage based on the matching conditions of disease indicators in different dimensions with the preset disease stage, and determine the indicator matching coefficient of the patient based on the number of matched disease indicators;

[0082] Based on the development data of disease indicators in different dimensions, determine the disease indicators whose change amounts match the preset disease stage, and use them as the change matching disease indicators, and determine the change indicator matching coefficient of the patient according to the number of change matching disease indicators;

[0083] The matching coefficient between the patient and the preset disease stage is determined based on the change index matching coefficient and the index matching coefficient.

[0084] It can be understood that the matching coefficient between the patient and the preset disease stage is determined based on the average value of the change index matching coefficient and the index matching coefficient.

[0085] Optionally, the method for determining the matching coefficient between the patient and the preset disease stage is:

[0086] S21 determines the disease indicator that matches the preset disease stage based on the matching of the disease indicators of different dimensions with the preset disease stage, and determines the disease indicator that matches the preset disease stage based on the development data of the disease indicators of different dimensions, and uses it as the change matching disease indicator;

[0087] Optionally, the above step S21 includes steps S211-S213, which are specifically:

[0088] S211 determines the disease indicators that match the preset disease stage based on the matching of the disease indicators of different dimensions with the preset disease stage. When the number of matched disease indicators is greater than the preset number of disease indicators, it is determined that the matching coefficient between the patient and the preset disease stage does not meet the requirement. When the number of matched disease indicators is not greater than the preset number of disease indicators, the process proceeds to step S212.

[0089] S212: When the number of matched disease indicators is within the preset indicator number range, the process proceeds to step S213; when the number of matched disease indicators is not within the preset indicator number range, the process proceeds to step S22;

[0090] S213 determines the disease indicators whose change amounts match the preset disease stage based on the development data of disease indicators in different dimensions, and uses them as change matching disease indicators. When the number of change matching disease indicators is greater than the preset number of change matching indicators, it is determined that the matching coefficient between the patient and the preset disease stage does not meet the requirements. When the number of change matching disease indicators is not greater than the preset number of change matching indicators, proceed to step S22.

[0091] S22 determines the disease matching coefficients of different disease indicators according to whether the disease indicator belongs to the matching disease indicator and the changing matching disease indicator;

[0092] Optionally, the above step S22 includes steps S221-S223, specifically:

[0093] S221 determines the disease matching coefficients of different disease indicators according to whether the disease indicator belongs to the matched disease indicator and the changed matched disease indicator. When there is a disease indicator with a disease matching coefficient greater than the preset disease matching coefficient, the process proceeds to step S222. When there is no disease indicator with a disease matching coefficient greater than the preset disease matching coefficient, the process proceeds to step S23.

[0094] S222: taking the disease indicators whose disease matching coefficient is greater than the preset disease matching coefficient as the disease matching indicators; when the number of disease matching indicators is greater than the preset number of disease indicators, determining that the matching coefficient between the patient and the preset disease stage does not meet the requirement; when the number of disease matching indicators is not greater than the preset number of disease indicators, proceeding to step S223;

[0095] S223 determines the disease screening matching coefficient with the disease matching coefficient of different disease matching indicators. When the disease screening matching coefficient is greater than the preset screening coefficient threshold, it is determined that the matching coefficient between the patient and the preset disease stage does not meet the requirements. When the disease screening matching coefficient is not greater than the preset screening coefficient threshold, proceed to step S23.

[0096] S23 determines the matching coefficient between the patient and the preset disease stage based on the disease matching coefficients of different disease indicators.

[0097] Furthermore, when the matching coefficient between the patient and the preset disease stage does not meet the requirement, it is determined that the patient needs to be subjected to genetic testing.

[0098] Specifically, Figure 4 As shown, the method for determining the change risk coefficient of the drug resistance of the target drug is:

[0099] The position of the mutation point corresponding to the target drug is used as the matching mutation position, and the number of patients with gene mutations corresponding to the matching mutation position is determined according to the gene mutation data corresponding to the matching mutation position;

[0100] The positional variation coefficients of different matching mutation positions are determined using the number of patients with corresponding gene mutations;

[0101] The risk coefficient of variation of drug resistance of the target drug is determined according to the positional variation coefficients of different matching mutation positions.

[0102] Furthermore, the position variation coefficient of the matching mutation position is determined according to the ratio of the number of patients with gene mutations corresponding to the matching mutation position to a preset number of patients.

[0103] It should also be noted that the risk coefficient of variation of the drug resistance of the target drug is determined according to the weighted sum of the positional variation coefficients of different matching mutation positions.

[0104] Optionally, the method for determining the change risk coefficient of drug resistance of the target drug is:

[0105] The position of the mutation point corresponding to the target drug is taken as the matching mutation position, and when the number of the matching mutation positions is greater than the preset number of mutation positions, the preset change risk coefficient is used to determine the change risk coefficient of the drug resistance of the target drug;

[0106] When the number of matching mutation positions is not greater than the preset number of mutation positions:

[0107] When the number of matching mutation positions is within a preset change number range:

[0108] Determine the number of patients with gene mutations corresponding to the matching mutation positions according to the gene mutation data corresponding to the matching mutation positions, when the average number of patients with gene mutations corresponding to different matching mutation positions is greater than a preset patient number threshold:

[0109] Then, a preset risk factor for variation is used to determine the risk factor for variation of drug resistance of the target drug;

[0110] When the average number of patients with gene mutations corresponding to different matching mutation positions is not greater than the preset patient number threshold:

[0111] The matching mutation positions where the number of patients with corresponding gene mutations is greater than a preset number limit value are used as screening mutation positions, and when the number of screening mutation positions is greater than a preset mutation position number threshold, a preset change risk coefficient is used to determine the change risk coefficient of drug resistance of the target drug;

[0112] When the number of mutation positions to be screened is not greater than the preset mutation position number threshold, the position change risk coefficient is determined based on the number of mutation positions to be screened and the number of patients with gene mutations corresponding to different mutation positions to be screened; when the position change risk coefficient does not meet the requirement, the preset change risk coefficient is used to determine the change risk coefficient of drug resistance of the target drug;

[0113] When the number of matching mutation positions is not within the preset change number range or the position change risk coefficient meets the requirements:

[0114] The positional variation coefficients of different matching mutation positions are determined using the number of patients with corresponding gene mutations, and the variation risk coefficient of drug resistance of the target drug is determined based on the positional variation coefficients of different matching mutation positions.

[0115] Further, determining whether it is necessary to perform genetic testing on the patient specifically includes:

[0116] Determine the risk correction coefficient of the patient based on the duration of medication for the patient, and determine the modified risk coefficient of the patient in combination with the variable risk coefficient of drug resistance of the patient;

[0117] A comprehensive risk coefficient is determined based on the patient's corrected risk coefficient, the patient's drug resistance risk, and the matching coefficient, and the comprehensive risk coefficient is used to determine whether genetic testing of the patient is required.

[0118] Specifically, the comprehensive risk coefficient is determined based on the patient's modified risk coefficient, the patient's drug resistance risk, and an average value of a matching coefficient.

[0119] It should be noted that when the comprehensive risk coefficient is greater than the preset comprehensive coefficient threshold, it is determined that the patient needs to undergo genetic testing.

[0120] Each embodiment in this specification is described in a progressive manner, and the same or similar parts between the embodiments can be referred to each other, and each embodiment focuses on the differences from other embodiments. In particular, for the device, equipment, and non-volatile computer storage medium embodiments, since they are basically similar to the method embodiments, the description is relatively simple, and the relevant parts can be referred to the partial description of the method embodiment.

[0121] The above is a description of a specific embodiment of the specification. Other embodiments are within the scope of the appended claims. In some cases, the actions or steps recorded in the claims can be performed in an order different from that in the embodiments and still achieve the desired results. In addition, the processes depicted in the drawings do not necessarily require the specific order or continuous order shown to achieve the desired results. In some embodiments, multitasking and parallel processing are also possible or may be advantageous.

[0122] The above description is only one or more embodiments of this specification and is not intended to limit this specification. For those skilled in the art, one or more embodiments of this specification may have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of one or more embodiments of this specification shall be included in the scope of the claims of this specification.

Claims

1. A blood gene detection method for tumors for drug guidance, characterized in that: Specifically include: Determine the medication matching period of the patient based on the medication data of the patient, determine the development data of different disease indicators of the patient within the medication matching period, and use the development data to determine that the drug resistance risk of the patient is within a preset risk interval, then proceed to the next step; Based on the disease indicators and the development data of the disease indicators, determining the matching of the disease indicators of the patient in different dimensions with the preset disease stages, and when determining based on the matching situation that the matching coefficient between the patient and the preset disease stage meets the requirements, proceeding to the next step; Determine the location and number of gene mutation points corresponding to the target drug, and determine the risk coefficient of drug resistance change of the target drug using the gene mutation data corresponding to the gene mutation points; Obtaining the duration of medication for the patient and the risk coefficient of drug resistance change, and determining whether it is necessary to perform genetic testing on the patient based on the patient's drug resistance risk and matching coefficient; The method for determining the matching coefficient between the patient and the preset disease stage is: Determine the disease indicators matching the preset disease stage based on the matching conditions between the disease indicators of different dimensions and the preset disease stage; Based on the development data of disease indicators in different dimensions, determine the disease indicator whose change amount matches the preset disease stage, and use it as the change matching disease indicator; Obtaining disease indicators that are both matching disease indicators and changing matching disease indicators, and using them as screening matching disease indicators, and determining a matching coefficient between the patient and a preset disease stage using the number of screening matching disease indicators; The method for determining the change risk coefficient of the drug resistance of the target drug is: The position of the mutation point corresponding to the target drug is used as the matching mutation position, and the number of patients with gene mutations corresponding to the matching mutation position is determined according to the gene mutation data corresponding to the matching mutation position; The positional variation coefficients of different matching mutation positions are determined using the number of patients with corresponding gene mutations; The risk coefficient of variation of drug resistance of the target drug is determined according to the positional variation coefficients of different matching mutation positions.

2. The method for blood gene detection for tumors for drug guidance according to claim 1, characterized in that: The medication matching period of the patient is the medication corresponding period of the patient's target drug.

3. The method for blood gene detection for tumors for drug guidance according to claim 1, characterized in that: The disease indicators include alpha-fetoprotein, carcinoembryonic antigen, CA125, and prostate-specific antigen.

4. The method for blood gene detection for tumors for drug guidance according to claim 1, characterized in that: The method for determining the patient's risk of drug resistance is: Determining abnormal change indicators in the patient's disease indicators based on the development data of the disease indicators; The drug resistance risk of the patient is determined according to the number of the abnormal change indicators.

5. The method for blood gene detection for tumors for drug guidance according to claim 4, characterized in that: The abnormal change index is a disease index whose change amount in the medication matching period does not meet the requirements.

6. The method for blood gene detection for tumors for drug guidance according to claim 1, characterized in that: When the patient's drug resistance risk is not within the preset risk range, when the patient's drug resistance risk is greater than the preset risk coefficient, it is determined that the patient needs to undergo genetic testing; when the patient's drug resistance risk is not greater than the preset risk coefficient, it is determined that the patient does not need to undergo genetic testing.

7. The method for blood gene detection for tumors for drug guidance according to claim 1, characterized in that: The position variation coefficient of the matching mutation position is determined according to the ratio of the number of patients with gene mutations corresponding to the matching mutation position to the preset number of patients.

8. The method for blood gene detection for tumors for drug guidance according to claim 1, characterized in that: The risk coefficient of variation of the drug resistance of the target drug is determined according to the weighted sum of the positional variation coefficients of different matching mutation positions.

9. The method for blood gene detection for tumors for drug guidance according to claim 1, characterized in that: Determine whether the patient needs to undergo genetic testing, including: Determine the risk correction coefficient of the patient based on the duration of medication for the patient, and determine the modified risk coefficient of the patient in combination with the variable risk coefficient of drug resistance of the target drug; A comprehensive risk coefficient is determined based on the patient's corrected risk coefficient, the patient's drug resistance risk, and the matching coefficient, and the comprehensive risk coefficient is used to determine whether genetic testing of the patient is required.

Images